For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. (HealthDay News) — For patients with inadequately controlled type 2 diabetes ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. HealthDay News — For patients with inadequately controlled type 2 diabetes ...

Opens in a new tab or window Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose.

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...

University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein ... professor of ...

The researchers will present their results at the spring meeting of the American Chemical Society (ACS). ACS Spring 2025 is being held March 23-27; it features about 12,000 presentations on a range of ...